While these pre-clinical observations strongly suggest that the combination of IFN-γ and bortezomib (or other NF-κB inhibitors) will have therapeutic benefit in ccRCC, they cannot be successfully exploited unless IFN-γ has direct access to RCC cells in vivo. This evidence concerns the gene NFKB1 and nonpapillary renal cell carcinoma.